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Abstract:  
Purpose: To report the clinical outcomes of intravitreal aflibercept therapy in eyes 
with neovascular AMD switched from intravitreal bevacizumab or ranibizumab.   
Methods: A retrospective review of 85 eyes treated in an as needed regimen in a 
clinical setting with bevacizumab or ranibizumab that were switched to 
aflibercept. Aflibercept was used in patients considered refractory to bevacizumab 
(persistent exudation despite consecutive injections) – group 1, and in patients on 
therapy with ranibizumab due to an institutional policy decision (controlled but 
requiring frequent injections) – group 2. Changes in best-corrected visual acuity 
(BCVA), anatomic response with the switch, central retinal thickness (CRT) and 
frequency of injections were compared. 
Results: Eighty five eyes of 69 patients were analyzed; 39 eyes in group 1 and 46 
in group 2. Mean follow-up time was 18 months prior to the switch and 8.3 months 
with aflibercept. Visual acuity showed stability with therapeutic switch in both 
groups (group1: 58.2 and 56.5, p=0.282; group2: 56.4 and 55.5, p=0.382) and the 
mean number of injections per month was significantly lower (0.76 vs 0.63, 
p<0.001).  With the switch to aflibercept, 90.6% of patients showed anatomic 
improvement with reduction of intra and/or subretinal fluid and both groups 
presented significant improvement in CRT (Group 1, 65.3 µm (p=0.051); Group 2,  
73.0 µm (p < 0.001)). 
Conclusion: Switching patients with neovascular AMD from bevacizumab or 
ranibizumab to aflibercept results in anatomical improvement and stabilized 
vision, while allowing injection intervals to be extended. 
 
Key Words: age-related macular degeneration, aflibercept, ranibizumab, 
bevacizumab, switch 
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Introduction: 
Age-related macular degeneration (AMD), specially the neovascular (wet or 
exudative) form, is one of the major causes of visual impairment in developed 
countries (Bressler, Bressler et al. 2003, Klein, Peto et al. 2004). 
Neovascular AMD is characterized by the development of new choroidal vessels 
that leak an exudative and hemorrhagic fluid, that eventually give rise to fibrotic 
scar tissue(Parmeggiani, Romano et al. 2012, Stewart 2012), and this pathological 
findings seem to be the basis of the clinical manifestations.  
The demonstration of vascular endothelial growth factor (VEGF)-A as the most 
prominent growth factor responsible for this pathophysiology(Adamis and Shima 
2005, Carneiro, Costa et al. 2012), led to a shift in the treatment options of AMD, 
specifically with intravitreal Anti-VEGF that significantly improved the outcome of 
these patients(Rosenfeld, Brown et al. 2006, Andreoli and Miller 2007, Brown, 
Michels et al. 2009, Carneiro, Falcao et al. 2010, Meyer and Holz 2011).  
Ranibizumab (Lucentis, Genentech/Roche) is a humanized monoclonal antigen-
binding fragment VEGF antibody that possesses the ability to bind all VEGF-A 
isoforms as well as their biologically active degradation products (Carneiro, Costa 
et al. 2012). Monthly injections of ranibizumab were proven efficient in the 
treatment of the neovascular form of AMD in the ANCOR and MARINA studies 
(Rosenfeld, Brown et al. 2006, Brown, Michels et al. 2009). 
Bevacizumab (Avastin, Genentech/Roche) is a full-length monoclonal antibody 
against all VEGF-A isoforms, known for its efficacy in many malignancies, such as 
breast, lung and colorectal cancers (Carneiro, Costa et al. 2012). Since 2005 it has 
been used off-label to treat neovascular AMD (Rich, Rosenfeld et al. 2006, 
Bashshur, Haddad et al. 2008, Carneiro, Falcao et al. 2010, Carneiro, Mendonca et 
al. 2012). 
Despite the same mechanisms of action, they have differences regarding molecular 
weight, affinity to VEGF and pharmacokinetic properties that seem to favor the use 
ranibizumab (Meyer and Holz 2011, Carneiro, Costa et al. 2012).  
Although this theoretical advantage, multiple studies, from which the CATT and 
IVAN trials stand out, have shown similar effects on visual acuity of patients with 
neovascular AMD treated with bevacizumab or with ranibizumab(Martin, Maguire 
et al. 2011, Chakravarthy, Harding et al. 2012, Martin, Maguire et al. 2012).  
Regardless of the therapeutic options available many patients with neovascular 
AMD still need continuous treatment to maintain the disease stable, others 
maintain some degree exudation regardless of the treatment and some develop a 
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need of higher doses to control the disease (tachyphylaxis)(Keane, Liakopoulos et 
al. 2008, Gasperini, Fawzi et al. 2012). 
Aflibercept (Eylea, Regeneron Pharmaceuticals) is a chimeric protein that results 
from the fusion of the Fc segment of a human Immunoglobulin G (IgG) to the 
second binding domain of the VEGFR-1 receptor and the third binding domain of 
the VEGFR-2 receptor(Holash, Davis et al. 2002, Stewart 2012). As a soluble 
receptor it possesses the ability to bind all isoforms of VEGF-A, VEGF-B and 
placental growth factor (PIGF) (Papadopoulos, Martin et al. 2012, Stewart 2012). 
Aflibercept has shown a higher affinity to VEGF-A (Stewart and Rosenfeld 2008, 
Papadopoulos, Martin et al. 2012) and a longer half-life(MW 2011). 
The randomized trials VIEW 1 and VIEW 2 proved that aflibercept was noninferior 
to ranibizumab, with the advantage of a more spaced need of treatment(Heier, 
Brown et al. 2012) which reduces the risk associated with intravitreal injections. 
As so, aflibercept appears to have both pharmacological and clinical advantage in 
the treatment of neovascular AMD, when compared with bevacizumab and 
ranibizumab. A drug with such higher VEGF-binding affinity may be useful in 
patients with persistent fluid despite treatment with ranibizumab and 
bevacizumab. 
In Hospital de São João intravitreal bevacizumab is the first line therapy for the 
treatment of neovascular AMD, essentially for economic reasons. The patients 
considered refractory to bevacizumab were switched to intravitreal ranibizumab, 
but since May 2013, when aflibercept became available, the salvage molecule used 
in our department became aflibercept. Those patients that were already on 
therapy with ranibizumab were switched to aflibercept, due to this non-medical 
board decision.  
Our purpose in this retrospective analysis was to compare the clinical outcomes 
after switching from intravitreal ranibizumab or bevacizumab to intravitreal 
aflibercept in the treatment of patients with chronic neovascular AMD. 
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Patients and methods:  
This retrospective, interventional, noncomparative review was performed at 
Hospital de São João, Porto, Portugal, a tertiary health care center. 
The study protocol was approved by the Ethics Committee of Health of Hospital de 
São João and followed the tents of the Declaration of Helsinki. 
Data were collected from patient’s charts and analyzed from November 2013 to 
March of 2014. We reviewed all patients with neovascular AMD on treatment with 
intravitreal bevacizumab or ranibizumab that were switched to intravitreal 
aflibercept. All patients were followed continuously at Hospital de São João and 
were treated as needed. All patients enrolled in the study had a minimum of three 
injections of bevacizumab or ranibizumab before the switch, and at least three 
aflibercept injections with subsequent follow-up.  
The patients analyzed had chronic neovascular AMD, with a long time of follow-up 
and a large number of injections before the switch to Aflibercept. We did not 
exclude patients that had done other therapies like photodynamic therapy with 
vertporfin (Visudyne, Novartis Ophtalmics) and pegaptanib (Macugen, Eyetech)) 
prior to the drug on the moment of the switch. Most patients that were switched 
from ranibizumab to aflibercept had done bevacizumab in the past, and had been 
unresponsive to bevacizumab. The patients who were submitted to cataract 
surgery during the follow-up period and patients with concomitant diseases in the 
study eye were excluded. Eighty five eyes of 69 patients were included and 
analyzed. 
During the follow-up the best corrected visual acuity (BCVA) was determined 
using Early Treatment Diabetic Retinopathy (ETDRS) charts. On first visit all 
patients were submitted to slit-lamp biomicroscopy, stereoscopic fundus 
examination, fluorescein angiography (FA) and macular optical coherence 
tomography (OCT) scanning. Only two experienced ophthalmologists (AMC and 
MSF) performed all FA and OCT evaluations at the first visit.  
The CNV lesions were classified angiographically into predominantly classic, 
minimally classic, occult with no classic and polypoidal choroidal vasculopathy 
(PCV). All angiographic lesions, even those with large areas of fibrosis, geographic 
atrophy, hemorrhage, or retinal pigment epithelium detachments more than 50% 
of the lesion’s size, were included in the study.  
The BCVA was not a criterion for treatment. If the patient was judged as having 
some potential visual recovery, intravitreal aflibercept therapy was proposed.  
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All patients were followed with a Spectralis HRA-OCT platform (Heidelberg 
Engineering, Germany). Macular thickness was measured manually on a scan that 
the observer interpreted as being on the fovea. 
At each follow-up visit all patients were reevaluated with ETDRS score, 
fundoscopic examination and OCT. Fluorescein angiography was repeated 
periodically, whenever an unexplained visual loss or an adverse event occurred. 
Retreatment was applied if intraretinal or subretinal fluid was present on OCT 
scans, if a new macular hemorrhage was present or if a new neovascular 
component of the lesion was identified on FA. 
Depending on the time period the patients were either treated with intravitreal via 
pars plana injection of 1.25mg of bevacizumab, 0.5mg of ranibizumab or 2mg of 
aflibercept. All treatments were performed in an operating room, under aseptic 
conditions. 
Patients were divided into two groups: patients considered refractory to 
bevacizumab (group 1) and patients switched from ranibizumab to aflibercept due 
to an institutional policy decision (group 2).  
Patients refractory to bevacizumab were defined as patients with persistent 
exudation after 3 or more consecutive monthly bevacizumab injections, regardless 
of best-corrected visual acuity. Signs of persistent exudation included subretinal 
fluid and/or intraretinal fluid on OCT. 
Patients on therapy with ranibizumab were recurrent (controlled with exudation 
suppressed, but requiring frequent injections).  
The main clinical outcome analyzed was the variation of the BCVA with the switch 
to aflibercept. Other outcomes analyzed were the anatomic response with the 
switch to aflibercept, the change in fluid and foveal thickness on OCT, the 
frequency of injections while receiving both drugs and the proportion of patients 
with visual acuity stability after switch to aflibercept.  
Statistical analysis was performed using the SPSS statistical software (Version 20.0 
for Windows, SPSS Inc, Chicago, IL). Intervals, rates and visual acuities were 
statistically compared between ranibizumab or bevacizumab and aflibercept 
treatments with paired student t test. Comparisons between groups were done 
with two-sample t test. Values in the text will be represented by mean (± standard 
deviation). A p value of ˂0.05 was considered statistically significant. 
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Results: 
Patient and Treatment Characteristics:  
Eighty five eyes of 69 patients with neovascular AMD who were switched from 
bevacizumab or ranibizumab to aflibercept met the inclusion criteria and were 
analyzed. Patient characteristics at the moment of aflibercept conversion are 
summarized in table 1.  
The mean age of patients was 76.6 years (range, 61-92 years). Thirty eight patients 
(55.1%) were female and 31 (44.9%) were male. Regarding the angiographic 
classification, there were 66 (77.6%) occult lesions, 7 (8.2%) predominantly 
classic lesions, 6 (7.1%) minimally classic lesions and 2 (2.4%) polypoidal 
choroidal vasculopathy (PCV) lesions. Four patients (4.7%) had large lesions with 
fibrosis and retinal pigment epithelial tears at the beginning of follow-up.  
Thirty nine eyes (45.9%) were refractory to bevacizumab (group 1) and 46 eyes 
(54.1%) were switched from treatment with ranibizumab due to a non-medical 
board decision (group 2).  
The mean time of treatment before the switch was 17.8 (±11.5) months overall, 
22.5 (±4.7) months for patients of group 1 and 13.8 (±13.8) months for patients of 
group 2.  
The mean number of bevacizumab injections in group 1 was 16.5 (±4.5) (range, 6-
24) and the mean number of ranibizumab injections in group 2 was 8.9 (±8.2) 
(range, 3-39). The mean injection rate per month was 0.74 in group 1 and 0.77 in 
group 2. 
Forty eyes of group 2 had done bevacizumab injections prior to the period of 
treatment with ranibizumab described in this report. In addition, 7 eyes also had 
history of previous treatment with photodynamic therapy with vertporfin 
(Visudyne, Novartis Ophtalmics) (3 in group 1 and 4 in group 2) and 1 eye with 
pegaptanib (Macugen, Eyetech) (group 2). 
At the moment of the therapeutic switch all patients of group 1 had signs of 
persistent exudation despite of consecutive monthly bevacizumab injections, 25 
eyes (64.1%) had persistent SRF, 14 eyes (35.9%) had persistent IRF and 13 eyes 
(33.3%) had persistent serous pigment epithelial detachment (PED). In group 2 all 
eyes had recurrent exudation requiring frequent injections. Serous PED were 
present in 6 eyes in group 2. 
The mean follow-up after the switch to aflibercept was 8.3 (±2.2) months overall, 
7.6 (±2.5) months for group 1 and 8.8 (±1.7) months for group 2. The mean 
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number of aflibercept injections in both groups was 5.1 (±1.7) (range, 3-9), 4.5 
(±1.6) in group 1 and 5.6 (±1.6) in group 2. 
Visual Outcomes:  
Visual outcomes are summarized in table 2. The mean BCVA before the switch was 
57.2 (±15.3) letters overall. Visual acuity showed stability with therapeutic switch 
in both groups (group 1: 58.2 vs 56.5, p = 0.282; group 2: 56.4 vs 55.5, p = 0.382).  
In group 1, 28 eyes (71.8%) maintained a stable visual acuity (within a variation of 
5 letters), 5 eyes (12.8%) lost more than 5 letters and 6 eyes (15.4%) had a gain 
superior than 5 letters. In group 2, 24 eyes (52.2%) maintained a stable visual 
acuity, 13 eyes (28.3%) lost and 9 eyes (19.6%) gained more than 5 letters.  
Anatomic Outcomes:  
With the switch to aflibercept central retinal thickness (CRT) was significantly 
reduced after 1 injection and at the end of follow-up in all groups (table 2). A mean 
decrease in CRT of 73.3 µm was noted after 1 injection of aflibercept (375.0 µm vs 
301.7 µm, p < 0.001). This improvement was maintained until the end of follow-up 
(375.0 µm vs 295.8 µm, p < 0.001). Group 1 and group 2 presented similar 
significant improvements (table 2). 
Qualitatively, after evaluation of all OCT studies available, there was an anatomic 
improvement in 77 eyes (90.6%) with reduction of exudation on OCT, 6 eyes 
(7.1%) were stable and only 2 eyes (2.4%) worsened. A dry OCT, without signs of 
subretinal or intraretinal fluid, was present in the last visit in 25 eyes (64.1%) of 
group 1 and in 33 eyes (71.7%) of group 2. A tear of the retinal pigment epithelium 
(RPE) occurred in one patient after 1 injection of aflibercept, but visual acuity 
remained stable and exudation improved. An extensive subretinal hemorrhage 
developed in another patient, with a significant vision loss and worsening of OCT. 
There were no cases of endophthalmitis or systemic complications registered 
during the follow-up period.  
Injections Outcomes:  
After the switch to aflibercept the injections intervals were significantly extended 
in all groups (table 2). The mean number of injections per month significantly 
diminished from 0.76 on prior therapy to 0.63 with aflibercept (p < 0.001) overall, 
from 0.74 to 0.60 (p < 0.001) in group 1 and from 0.77 to 0.65 (p = 0.016) in group 
2. 
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Discussion 
Since the discovery of the importance of VEGF-A in the pathophysiology of 
neovascular AMD, the standard treatment suffered a shift towards anti-VEGF 
drugs. 
Bevacizumab was regularly used as first treatment option, although AMD was not 
one of its approved indications. Ranibizumab demonstrated in the ANCHOR and 
MARINA trials effectiveness for treating the disease. The molecular weight, affinity 
to VEGF and pharmacokinetic properties gave ranibizumab a theoretical 
advantage. However, after the results of the CATT trial, the use of bevacizumab has 
become more consensual.  
Our purpose was to evaluate the response to aflibercept in patients resistant to 
bevacizumab and in patients that needed continuous injections of ranibizumab. 
Therefore we evaluated the variation of the BCVA, the change in fluid and foveal 
thickness on OCT after the switch to aflibercept and the frequency of injections 
prior and after the switch. 
The anatomic response was the outcome that showed better improvements, which 
seems to confirm the theoretical advantage of aflibercept in terms of 
pharmacokinetic and its ability to bind not only to VEGF-A and VEGF-B, but also 
placental growth factor (PIGF)(Papadopoulos, Martin et al. 2012, Stewart 2012). A 
statistically significant decrease in CRT occurred after the switch to aflibercept. 
This decrease was noted after the first injection and maintained until the end of 
the follow-up. Exudation on OCT was largely decreased, resulting in absence of 
subretinal or intraretinal fluid in majority of patients. It should be noted that these 
anatomical gains were present in both the group refractory to bevacizumab and 
the group previously treated with ranibizumab. 
It is possible that the better anatomic response that we documented may be 
attributable to a more potent effect of aflibercept, especially in the cases that did 
not respond at all to bevacizumab. A controversial aspect of the treatment of 
neovascular AMD is the possibility of tachyphylaxis (Keane, Liakopoulos et al. 
2008, Gasperini, Fawzi et al. 2012) with the long term usage of ranibizumab in 
patients that were previously responsive to this drug. This may be the case of some 
of our patients in group 2. Due to its pharmacological properties, aflibercept can 
bypass this problem and this may be the basis of its superior results in our second 
group. As ranibizumab was proven effective in the short-term treatment we can 
speculate that there may not be a difference in effectiveness between this two 
drugs, but rather that there was still not enough time to develop tachyphylaxis 
with aflibercept. If this was to occur, we could possibly find similar results with a 
switch from aflibercept to ranibizumab. A longer follow-up with our patients may 
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prove or not the development of tachyphylaxis and the worsening of anatomic 
parameters with long-term aflibercept. 
The BCVA showed a very small variation after the switch, with both groups 
keeping a stable visual acuity. 
Various clinical trials showed an improvement in visual acuity after treatment with 
both bevacizumab and ranibizumab in treatment naïve patients (Martin, Maguire 
et al. 2011, Martin, Maguire et al. 2012) or in a clinical setting(Carneiro, Mendonca 
et al. 2012). Our patients were not treatment naïve. A visual improvement was not 
demonstrated in our cohorts of patients with aflibercept regardless of the superior 
anatomic outcomes in both groups. This may be due to the fact that this is a late 
stage of the disease, with profound structural changes and a long history of 
treatment with other agents and not the inability of aflibercept. Therefore it is 
legitimate to think that anti-VEGF drugs may be unable to obtain any visual gain in 
neovascular AMD with such a long natural history. The clinical trials have shown 
that patients with wet AMD improve visual acuity with the first injections, but after 
the initial period, a plateau stage is reached with monthly injections without any 
visual improvements. 
On the other hand we must question if on the long-term, persistence of exudation 
can have deleterious effects on retinal function. All the patients included in the 
study were either poor responders to bevacizumab or patients that needed 
frequent injections with ranibizumab. Even though the switch did not lead to an 
increase in visual acuity despite the anatomic improvement, it is plausible that if 
the retina is kept dry, on the long-term, visual acuity will remain stable whilst 
retinas that always maintain a certain level of exudation may eventually lose vision 
with time. On the other hand, CATT has described a higher evolution to geographic 
atrophic AMD in patients whose neovascular AMD was controlled with monthly 
ranibizumab injections (Martin, Maguire et al. 2012). 
It is possible that the more pronounced effect on the neovascular activity that we 
describe for aflibercept, could lead to progression of geographic atrophy. However, 
the follow-up period of our study is too short to determine these changes. 
With the switch the injections intervals were extended in all groups and the overall 
mean number of injections per month diminished. 
The results we obtained follow the same contour as the papers published 
regarding this subject. 
Yonekawa et al reported on 102 eyes of 94 patients with either refractory or 
recurrent neovascular AMD switched from bevacizumab or ranibizumab to 
aflibercept. A mean follow-up of 18 weeks showed that vision was stable while 
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anatomic outcomes (central macular thickness) improved. After the switch 
injection intervals were extended (Yonekawa, Andreoli et al. 2013).  
Bakall et al analyzed 36 eyes from 31 patients that were resistant to treatment 
with ranibizumab or resistant to treatment with bevacizumab. Once again an 
anatomic improvement was established by reduction of either subretinal or 
intraretinal fluid and a decrease of the central macular thickness. No significant 
change in visual acuity was described.(Bakall, Folk et al. 2013) Cho et al and Ho et 
al obtained similar outcomes in their research. (Cho, Shah et al. 2013, Ho, Yeh et al. 
2013)  
Kumar et al analyzed 34 eyes of 33 patients with persistent subretinal and/or 
intraretinal fluid despite previous treatments with ranibizumab. An anatomic 
improvement was described with the switch to aflibercept. Unlike any other study 
described in this paper, there was a significant improvement in visual acuity. 
Visual gain was described only after 6 months of follow-up. No visual gain was 
obtained after the third consecutive injection.(Kumar, Marsiglia et al. 2013) 
The major strength of our study is the possibility to define two different groups 
that represent the common problems of anti-VEGF’s treatment in neovascular 
AMD. With this we can evaluate the expected response to aflibercept in the normal 
clinical practice and the possibility of establishing it as a good alternative to the 
commonly used bevacizumab and ranibizumab.  
In group 2, due to the institutional decision to switch from ranibizumab to 
aflibercept, we can assess the effect of aflibercept in the patients that were still 
responding to ranibizumab (although needing recurrent injections) and thus 
showing that patients with poor responses to ranibizumab may respond to 
aflibercept. 
Additionally, in our study, patients were used as their own control which allowed a 
direct comparison between drugs within the same parameters. 
The limitations of our study go beyond its retrospective noncomparative nature, 
and many of them are consequence of its realization in a clinical setting. One 
limitation is that there was a lack of standardized protocols regarding the decision 
to treat or not the patient as such some bias of this parameter depends on the 
practice of the treating physician. 
Another limitation of the study is the inability to evaluate patients that had poor 
responses to aflibercept and could be switched back to either ranibizumab or 
bevacizumab, as the mean follow-up time was too short to evaluate its long term 
effects. 
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Most patients had a chronic neovascular AMD with a long time of follow-up and a 
large number of injections before the switch to aflibercept. Moreover, a lot of 
patients were not treatment naïve, having received other treatments prior to the 
drug at the moment of switch.  
These biases, which arise from the chronicity of the disease and the recent 
availability of aflibercept, may influence the results and conceal the true effects of 
aflibercept.  
As such, a long term follow-up of a cohort of naive patients would be the best 
option to obtain a more valid conclusion regarding the visual effects of aflibercept, 
and to elucidate us about the possible evolution of a continuously dry neovascular 
AMD to a condition baring a worse prognosis. Once again, it is very hard to obtain a 
cohort in the clinical setting that meets these criteria.  
In conclusion, our results show that switching patients with neovascular AMD from 
bevacizumab or ranibizumab to aflibercept results in anatomical improvement and 
stabilized vision, while allowing injection intervals to be extended, and therefore 
this drug appears to be a valuable tool in the treatment of neovascular AMD. 
Switching between different classes of anti-VEGF drugs should be equated in non-
responsive or patients with frequent recurrences. 
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Figures and figures legends 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Patient initially treated with bevacizumab (group 1) that 
ended developing resistance to the drug (A and B). 
C represents the moment that it was decided to switch to 
aflibercept.  
D is after one injection of aflibercept.  
E is after the three injections of aflibercept.  
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Fig. 2. Patients previously treated with ranibizumab (group 2) with 
a good response (A and B). 
Later on had recurrence with this drug (C) and it was proposed to 
treatment with aflibercept. 
D is after one injection of aflibercept. 
E is after three injections of aflibercept. 
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Tables 
 
Table 1. Switching to Aflibercept in Patients with Chronic 
Neovascular AMD - Patient and Treatment Characteristics 
Eyes (Patients) 85 (69) 
Age, mean (range) 76.6 (61-92) 
Women, n (%) 
Angiographic Classification, n (%) 
     Occult with no Classic 
     Predominantly Classic  
     Minimally Classic 
     Polipoidal Choroidal Vasculopathy 
38 (55.1%) 
 
66 (77.6%) 
7 (8.2%) 
6 (7.1%) 
2 (2.4%) 
Eyes Refractory Bevacizumab, n (%) 39 (45.9%) 
Eyes on Treatment with Ranibizumab, n (%) 46 (54.1%) 
Months on Therapy, mean (±SD) 
     Prior to Switch 
     Aflibercept  
Number Injections, mean (±SD) 
     Prior to Switch 
     Aflibercept 
 
17.8 (±11.5) 
8.3 (±2.2) 
 
12.4 (±7.7) 
5.1 (±1.7) 
SD, Standard Deviation. 
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Table 2. Outcomes After Switching to Aflibercept in Patients with Chronic Neovascular AMD 
  
All 
(N = 86) 
 
 
P 
Group 1 
Bevacizumab 
(N = 39) 
 
 
P 
Group 2 
Ranibizumab 
(N = 47) 
 
 
P 
Mean BCVA (ETDRS score) 
     Before Switch (±SD) 
     Final (±SD) 
 
57.2 (±15.3) 
56.0 (±17.4) 
 
 
0.162 
 
58.2 (±16.8) 
56.5 (±18.4) 
 
 
0.282 
 
56.4 (±14.0) 
55.5 (±16.7) 
 
 
0.382 
Mean CRT (μm) 
     Before Switch (±SD) 
     After 1 Injection (±SD) 
     Final (±SD) 
 
375.0 (±178.0) 
301.7 (±122.8) 
295.8 (±128.7) 
 
 
< 0.001 
*< 0.001 
 
374.1 (±188.1) 
298.1 (±96.6) 
308.8 (±132.4) 
 
 
0.009 
*0.051 
 
375.7 (±171.1) 
304.7 (±142.3) 
284.7 (±125.9) 
 
 
< 0.001 
*< 0.001 
Injections per Month  
     Previous (±SD) 
     Aflibercept (±SD) 
 
0.76 (±0.26) 
0.63 (±0.17) 
 
 
<0.001 
 
0.74 (±0.17) 
0.60 (±0.18) 
 
 
<0.001 
 
0.77 (±0.31) 
0.65 (±0.16) 
 
 
0.016 
Outcomes expressed as mean values (±SD); BCVA expressed in ETDRS score; CRT expressed in μm.  
SD, Standard Deviation; BCVA, Best Corrected Visual Acuity; CRT, Central Retinal Thickness; *P values were also compared to values before the switch.  
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